Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dabholkar

Showing results (91-100 of 136) with videos related to

Pageof 14
Sort By:
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|August 16, 2021
Repurposing methylene blue in the management of COVID-19: Mechanistic aspects and clinical investigationsNeha Dabholkar, Srividya Gorantla, Sunil Kumar Dubey, et al.
International Journal of Molecular Medicine|December 16, 1998
Alternative splicing of ERCC1 and cisplatin-DNA adduct repair in human tumor cell linesJ J Yu, C Mu, M Dabholkar, et al.
The Indian Journal of Radiology & Imaging|January 12, 2026
Establishing Diagnostic Reference Level for Adult Abdomen and Pelvis CT Scans: A Benchmarking Study across BMI GroupsJaseemudheen M M, Raghuraja U, Sri Krishna U, et al.
Mutation Research|January 1, 1993
Expression of excision repair genes in non-malignant bone marrow from cancer patientsM Dabholkar, F Bostick-Bruton, C Weber, et al.
Journal of the National Cancer Institute. Monographs|January 1, 1993
Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cellsR J Parker, M D Dabholkar, K B Lee, et al.
Journal of the National Cancer Institute|October 7, 1992
ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patientsM Dabholkar, F Bostick-Bruton, C Weber, et al.
Biochemical Pharmacology|November 15, 2000
Increased mRNA levels of xeroderma pigmentosum complementation group B (XPB) and Cockayne's syndrome complementation group B (CSB) without increased mRNA levels of multidrug-resistance gene (MDR1) or metallothionein-II (MT-II) in platinum-resistant human ovarian cancer tissuesM Dabholkar, K Thornton, J Vionnet, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 30, 2021
Quality by design (QbD) in the formulation and optimization of liquid crystalline nanoparticles (LCNPs): A risk based industrial approachTejashree Waghule, Neha Dabholkar, Srividya Gorantla, et al.
International Journal of Oncology|May 6, 2011
Platinum-sensitive and platinum-resistant ovarian cancer tissues show differences in the relationships between mRNA levels of p53, ERCC1 and XPAJ Yu, M Dabholkar, W Bennett, et al.
Oncology Reports|August 19, 2000
Evidence for in the appearance of mRNAs of nucleotide excision repair genes, in human ovarian cancer tissuesE Reed, M Dabholkar, K Thornton, et al.
Pageof 14

Showing results (91-100 of 136) with videos related to

Sort By:
Pageof 14
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|August 16, 2021
Repurposing methylene blue in the management of COVID-19: Mechanistic aspects and clinical investigationsNeha Dabholkar, Srividya Gorantla, Sunil Kumar Dubey, et al.
International Journal of Molecular Medicine|December 16, 1998
Alternative splicing of ERCC1 and cisplatin-DNA adduct repair in human tumor cell linesJ J Yu, C Mu, M Dabholkar, et al.
The Indian Journal of Radiology & Imaging|January 12, 2026
Establishing Diagnostic Reference Level for Adult Abdomen and Pelvis CT Scans: A Benchmarking Study across BMI GroupsJaseemudheen M M, Raghuraja U, Sri Krishna U, et al.
Mutation Research|January 1, 1993
Expression of excision repair genes in non-malignant bone marrow from cancer patientsM Dabholkar, F Bostick-Bruton, C Weber, et al.
Journal of the National Cancer Institute. Monographs|January 1, 1993
Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cellsR J Parker, M D Dabholkar, K B Lee, et al.
Journal of the National Cancer Institute|October 7, 1992
ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patientsM Dabholkar, F Bostick-Bruton, C Weber, et al.
Biochemical Pharmacology|November 15, 2000
Increased mRNA levels of xeroderma pigmentosum complementation group B (XPB) and Cockayne's syndrome complementation group B (CSB) without increased mRNA levels of multidrug-resistance gene (MDR1) or metallothionein-II (MT-II) in platinum-resistant human ovarian cancer tissuesM Dabholkar, K Thornton, J Vionnet, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 30, 2021
Quality by design (QbD) in the formulation and optimization of liquid crystalline nanoparticles (LCNPs): A risk based industrial approachTejashree Waghule, Neha Dabholkar, Srividya Gorantla, et al.
International Journal of Oncology|May 6, 2011
Platinum-sensitive and platinum-resistant ovarian cancer tissues show differences in the relationships between mRNA levels of p53, ERCC1 and XPAJ Yu, M Dabholkar, W Bennett, et al.
Oncology Reports|August 19, 2000
Evidence for in the appearance of mRNAs of nucleotide excision repair genes, in human ovarian cancer tissuesE Reed, M Dabholkar, K Thornton, et al.
Pageof 14